Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Stason Pharmaceuticals, Inc.
WARNING LETTER
•Stason Pharmaceuticals, Inc.•October 25, 2019

Stason Pharmaceuticals, Inc. – FDA Warning Letter, Oct 25, 2019

Record Details

On July 8, 2020, the FDA issued a Warning Letter to Stason Pharmaceuticals, Inc. following an inspection from October 3-25, 2019, at their Irvine, CA facility. The inspection revealed significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals, rendering their drug products adulterated under 21 U.S.C. 351(a)(2)(B).

Key violations include: 1. **Failure to thoroughly investigate discrepancies (21 CFR 211.192):** The firm failed to determine a root cause for out-of-specification (OOS) dissolution results for temozolomide capsules, even after a relaxed specification was approved and a lot was recalled. Their investigation into dissolution variability was inadequate, lacking a clear root cause and effective CAPA. Interim measures for cleaning issues post-methotrexate tablet manufacture were also insufficient. The FDA requested comprehensive dissolution testing results, stability program details, and shipped lot numbers.

2. **Inadequate controls over computer systems (21 CFR 211.68(b)):** The firm lacked sufficient controls to ensure electronic test data integrity. Specifically, the spectrophotometer used for product release and stability testing allowed data files to be deleted without quality unit knowledge. The firm's response was inadequate as it failed to include a comprehensive review of all laboratory instruments for appropriate user roles and lacked a

Company
Stason Pharmaceuticals, Inc.
Inspection date
October 25, 2019
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations IV
People
  • Mariza Jafary
  • Steven E. Porter (Program Division Director)
View Company Profile

ID · 785e47c0-b5ba-4ef1-8e59-3453b4f044e1

Violation Codes8
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.19221 CFR 211.68(b)FD&C Act 501(a)(2)(B)21 CFR 211.3421 U.S.C. 356C(b)

Full citation text and observation details available on the Dashboard.

Other documents for Stason Pharmaceuticals, Inc.
  • 483 - 2021-04-13April 13, 2021
  • 483 - 2019-10-25October 25, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Stason Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.